Literature DB >> 31996968

Differentiating microcystic meningioma from atypical meningioma using diffusion-weighted imaging.

Ke Xiaoai1, Zhou Qing1, Han Lei1, Zhou Junlin2.   

Abstract

PURPOSE: Microcystic meningioma (MCM) appears similar to atypical meningioma(AM) as per conventional diagnostic imaging. However, considering their different recurrence rate and prognosis, accurate differential diagnosis is essential for determine the appropriate treatment strategy. The aim of the study was to differentiate MCM from AM by diffusion-weighted imaging (DWI), in order to provide the basis for accurate preoperative diagnosis.
METHODS: The preoperative clinical data, conventional MRI and DWI data of 15 MCM and 30 AM cases were retrospectively analyzed. The average apparent diffusion coefficient (ADCmean), minimum ADC (ADCmin) and normalized ADC (nADC) between MCM and AM were compared using two sample t-tests. The value of ADCmean, ADCmin and nADC in the differential diagnosis of MCM and AM were calculated by the receiver operating curve (ROC) analysis.
RESULTS: The ADCmean (1.06 ± 0.10 vs 0.80 ± 0.11 × 10-3 mm2/s; P < 0.001), ADCmin (0.99 ± 0.10 vs 0.74 ± 0.12 × 10-3 mm2/s; P < 0.001) and nADC (1.45 ± 0.17 vs 1.07 ± 0.17; P < .0001) were significantly higher in MCM compared to AM. ADCmean of 0.91 × 10-3 mm2/s showed an optimum area under the ROC curve of 0.967 ± 0.022, and distinguished between MCM and AM with 86.67% sensitivity, 100% specificity and 88.89% accuracy. In addition, its positive and negative predictive values were 96.29% and 77.78% respectively.
CONCLUSIONS: DWI can differentially diagnose MCM and AM, and ADCmean is a potential quantitative tool that can improve preoperative diagnosis of both tumors.

Entities:  

Keywords:  Anaplastic meningioma; Apparent diffusion coefficient (ADC); Diffusion weighted imaging (DWI); Magnetic resonance imaging (MRI); Microcystic meningioma

Mesh:

Year:  2020        PMID: 31996968     DOI: 10.1007/s00234-020-02374-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  34 in total

1.  Diffusion weighted imaging may help differentiate intracranial hemangiopericytoma from meningioma.

Authors:  Jai Jai Shiva Shankar; Luke Hodgson; Namita Sinha
Journal:  J Neuroradiol       Date:  2018-11-27       Impact factor: 3.447

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images.

Authors:  J H Burdette; A D Elster; P E Ricci
Journal:  Radiology       Date:  1999-08       Impact factor: 11.105

4.  Is diffusion-weighted imaging useful in grading and differentiating histopathological subtypes of meningiomas?

Authors:  S Eser Sanverdi; Burce Ozgen; Kader K Oguz; Melike Mut; Anil Dolgun; Figen Soylemezoglu; Aysenur Cila
Journal:  Eur J Radiol       Date:  2011-07-01       Impact factor: 3.528

Review 5.  Whole-body diffusion-weighted MR imaging in cancer: current status and research directions.

Authors:  Anwar R Padhani; Dow-Mu Koh; David J Collins
Journal:  Radiology       Date:  2011-12       Impact factor: 11.105

Review 6.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

7.  MRI of intracranial meningiomas: correlations with histology and physical consistency.

Authors:  P Carpeggiani; G Crisi; C Trevisan
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

8.  Microcystic variant of meningioma: a light-microscopic and ultrastructural study.

Authors:  G M Kleinman; T Liszczak; E Tarlov; E P Richardson
Journal:  Am J Surg Pathol       Date:  1980-08       Impact factor: 6.394

9.  Microcystic meningioma: importance of obvious hypointensity on T1-weighted magnetic resonance images.

Authors:  Chi-Jen Chen; Ying-Chi Tseng; Hui-Ling Hsu; Shih-Ming Jung
Journal:  J Comput Assist Tomogr       Date:  2008 Jan-Feb       Impact factor: 1.826

Review 10.  Meningioma.

Authors:  Ali-Reza Fathi; Ulrich Roelcke
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

View more
  5 in total

1.  Differentiation of intracranial solitary fibrous tumor/hemangiopericytoma from atypical meningioma using apparent diffusion coefficient histogram analysis.

Authors:  Xianwang Liu; Juan Deng; Qiu Sun; Caiqiang Xue; Shenglin Li; Qing Zhou; Xiaoyu Huang; Hong Liu; Junlin Zhou
Journal:  Neurosurg Rev       Date:  2022-03-18       Impact factor: 3.042

2.  T1 and ADC histogram parameters may be an in vivo biomarker for predicting the grade, subtype, and proliferative activity of meningioma.

Authors:  Tiexin Cao; Rifeng Jiang; Lingmin Zheng; Rufei Zhang; Xiaodan Chen; Zongmeng Wang; Peirong Jiang; Yilin Chen; Tianjin Zhong; Hu Chen; PuYeh Wu; Yunjing Xue; Lin Lin
Journal:  Eur Radiol       Date:  2022-08-12       Impact factor: 7.034

3.  Are the clinical manifestations of CT scan and location associated with World Health Organization histopathological grades of meningioma?: A retrospective study.

Authors:  Razieh Behzadmehr; Rezvaneh Behzadmehr
Journal:  Ann Med Surg (Lond)       Date:  2021-04-30

4.  Apparent Diffusion Coefficient Values and Dynamic Contrast-Enhanced Magnetic Resonance Perfusion are Potential Predictors for Grading Meningiomas.

Authors:  Sri Andreani Utomo; Abdul Hafid Bajamal; Yuyun Yueniwati; Irfan Deny Sanjaya; Dyah Fauziah
Journal:  Int J Med Sci       Date:  2022-07-18       Impact factor: 3.642

5.  Differentiating between non-functioning pituitary macroadenomas and sellar meningiomas using ADC.

Authors:  Jing Zhang; Zhiyong Zhao; Li Dong; Tao Han; Guojin Zhang; Yuntai Cao; Junlin Zhou
Journal:  Endocr Connect       Date:  2020-12       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.